New to the Huntington's Disease Lighthouse?
 Welcome to the HDlighthouse!
 Getting started.
 
Home \ Treatment & Care \ Treatment \ Drugs \ Lax101 \ Human \ Updates
  HD Lighthouse Editors Comment: Message from Crispin Bennett, PhD Research Information Manager 30-May-2001

Posted to HDLighthouse: 23 Jan 2002
HDL Update: LAX-101 Trial


The trial is now up and running...

"We at Laxdale follow with great interest all that is posted on the HD Lighthouse Website. We thought you would like to know about the LAX-101 trial.

The trial is now up and running at centres in the UK, USA, Canada and Australia. Recruitment for the trial is expected to complete in the near future. The treatment lasts for 12 months in each patient. Only when the last patient has completed the study will the code for all the patients be broken so that the statisticians can identify which patients are on LAX-101 and which are on placebo. Because the trial is double blind neither we nor any of the investigators will know what is happening until the code is broken and all the results are analysed. We expect that it will be a few months before all the data can be collected from all the centers and fully analysed, so that it will be in 2003 before we finally know what has happened. We will then submit the data to the FDA and to regulators in other countries and also to a medical journal for publication. The full results will not be made public until they have been published in a medical journal.

Please understand that this has to be a careful and thorough process. This trial is being conducted by some of the world's leading investigators in Huntington's Disease and it is intended to be large enough to give a definitive answer one way or the other as to whether LAX-101 works. It is our intention that the evidence collected should be strong enough to persuade regulators, governments and insurance companies that LAX-101 should be provided to all patients who might benefit.

Without doing this sort of study we could end up with a treatment that works but which is not available to most patients because those who must approve it and pay for it are not convinced by the evidence. We hope that everyone will understand what we are trying to do."

All of us at Laxdale, and at our US partner Amarin, continue to work as rapidly and effectively as possible to bring LAX-101 forward. We appreciate the support and goodwill you have shown us thus far and will continue to work to earn it in the future.

All the best,

David Horrobin
==============
Laxdale Ltd, Kings Park House, Laurelhill Business Park, Stirling FK7 9JQ, Scotland.
Tel: + 44 (0)1786 476000
Fax: + 44 (0)1786 473137
e-mail: admin@laxdale.co.uk

Source: Crispin Bennett, PhD Research Information Manager 30-May-2001

Read the HDAC/HDLighthouse Forum. Post your comments
   
 

Amarin Phase III LAX-101 Huntington Trial
Near term focus is to maintain progress with LAX-101 for Huntington's disease. We expect an additional U.S. Phase III clinical ...
Jerry Lampson
Posted to HDL: 25 Mar 2004

LAX-101 Additional Phase 3 Trials
LAX-101 is a novel and proprietary product being developed for treatment of the symptoms of Huntington's Disease (HD). LAX-101 has ...
Jerry Lampson
Posted to HDL: 03 Feb 2003

Amarin Readies LAX-101 Launch
Amarin announced today that it has completed a private placement of 6,093,727 ordinary shares to a group of accredited investors ...
Adapted from Amarin press release by Jerry Lampson
Posted to HDL: 28 Jan 2003

$500,000,000 Market For Huntingtons' Disease Treatment
Fast track approval of LAX-101 for the treatment of Huntington's disease. Market for LAX-100 estimated at $500,000,000 ... ...
Adapted www.marketwatch.com by Jerry Lampson
Posted to HDL: 04 Dec 2002

LAX-101 AND HUNTINGTON'S DISEASE: QUESTIONS AND ANSWERS
Questions and answers about LAX-101, the first statistically significant treatment for Huntington's disease in phase 3 clinical trials. ... ...
Crispin Bennett PhD
Posted to HDL: 04 Nov 2002

LAX-101 Study Results in Huntington's Disease
Amarin Corporation Announces Encouraging Preliminary Results of LAX-101 Pivotal Study in Huntington's Disease ... ...
Crispin Bennett PhD, Research Information Manager, Laxdale Ltd.
Posted to HDL: 28 Oct 2002

**** HD Treatment LAX101 To Be Available
We knew it all along. HD is a treatable condition. LAX101 is expected be available in the first half of ...
From HDL contributor Ron Hartley 17Jun02
Posted to HDL: 17 Jun 2002

****LAX-101 NPL's Breakthrough
LAX-101 and NPLs Demonstrate Benefit in the Treatment of Huntington's Disease in Separate Phase II Studies..Monash study was halted on ...
Amarin Press Release
Posted to HDL: 23 Jan 2002

LAX-101 Presentation
LAX-101, pure ethyl eicosapentaenoate (EPA), is in trial for the treatment of HD. LAX-101 is manufactured by Laxdale in the ...
Rick Stewart, CEO of Amarin, Salomon Smith Barney 2001 Healthcare Conference
Posted to HDL: 21 Sep 2001

LAX-101 Trial, The trial is now up and running
We at Laxdale follow with great interest all that is posted on the HD Lighthouse Website. We thought you would ...
Crispin Bennett, PhD Research Information Manager 30-May-2001
Posted to HDL: 30 May 2001
[an error occurred while processing this directive]

Disclaimer & Privacy Policy | Welcome | Site Feedback Marsha@HDLighthouse.org